Background
Dengue infects ~390 million people annually. No approved antiviral therapy exists. Previous clinical trials of host-directed therapies failed consistently — not because the targets were wrong, but because they enrolled the wrong patients (already hospitalised) at the wrong time (viral peak already passed). A critical gap remains: no early, low-cost intervention for ambulatory patients to prevent progression to severe dengue.
Hypothesis
In ambulatory dengue patients presenting within 72 hours of fever onset, oral N-acetylcysteine (600–1200 mg twice daily for 5–7 days) given to individuals identified by simple clinical risk scores (age >40, secondary infection by rapid NS1/IgG test, comorbidities, or warning signs) will reduce progression to severe dengue and hospitalisation by ≥40% compared to standard supportive care alone.
Mechanistic Rationale
DENV infection drives oxidative stress via mitochondrial dysfunction and NOX activation in endothelial cells, generating ROS that trigger inflammation, vascular hyperpermeability, and plasma leakage — the hallmarks of severe dengue. NAC has a dual mechanism: (1) antioxidant — scavenges ROS, restores glutathione, blocks NOX- and mitochondrial-derived ROS in endothelial models; (2) antiviral — dose-dependently reduces DENV replication, E protein expression, and infectivity while upregulating RIG-I and MDA5 innate immune sensors. In severe dengue-associated acute liver failure, IV NAC showed 97% survival vs ~50% expected mortality in a retrospective series of 30 adults.
Why Previous Trials Failed
Past tria





























